Skip to main
ACXP

ACXP Stock Forecast & Price Target

ACXP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Acurx Pharmaceuticals has received advantageous feedback from both the FDA and EMA regarding its lead candidate, ibezapolstat (IBZ), positioning it favorably for the upcoming Phase 3 trial focusing on adult populations. The observed antimicrobial activity and a favorable safety profile for IBZ, particularly in the context of treating infections from priority pathogens, bolsters the company's prospects in the biopharmaceutical market. Additionally, the recent positive opinion from the Pediatric Committee of the EMA on the Pediatric Investigation Plan for IBZ further expands the potential application of this antibiotic candidate, enhancing Acurx's strategic outlook.

Bears say

Acurx Pharmaceuticals faces significant challenges in its valuation, primarily due to the high costs associated with developing clinical-stage biopharmaceuticals amid a competitive market for antibiotic therapies. The company operates in a sector with substantial regulatory hurdles and uncertainties surrounding the efficacy and market adoption of its Gram-positive selective spectrum antibiotic candidates. Furthermore, ongoing financing needs may result in dilution for existing shareholders, and projected timelines for product development could extend longer than anticipated, impacting investor confidence and overall stock performance.

ACXP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Acurx Pharmaceuticals LLC (ACXP) Forecast

Analysts have given ACXP a Strong Buy based on their latest research and market trends.

According to 1 analysts, ACXP has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Acurx Pharmaceuticals LLC (ACXP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.